P Richard Harrigan

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. pmc Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
    P R Harrigan
    Clinical Virology, Glaxo Wellcome Research and Development, Stevenage, United Kingdom
    J Virol 72:3773-8. 1998
  2. ncbi request reprint Selection of drug-resistant HIV
    P R Harrigan
    BC Centre for Excellence in HIV AIDS, Vancouver, Canada
    Trends Microbiol 7:120-3. 1999
  3. pmc Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS
    Adrian R Levy
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
    Lipids Health Dis 4:4. 2005
  4. pmc Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART
    Robert S Hogg
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    PLoS Med 3:e356. 2006
  5. ncbi request reprint Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy
    Magdalena A Recsky
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    J Infect Dis 190:285-92. 2004
  6. doi request reprint Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial
    Rachel A McGovern
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 61:279-86. 2012
  7. ncbi request reprint Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy
    Zabrina L Brumme
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    Antivir Ther 8:91-6. 2003
  8. ncbi request reprint Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy
    P Richard Harrigan
    British Columbia Centre for Excellence in HIV AIDS, and Department of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 191:339-47. 2005
  9. ncbi request reprint Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy
    Zabrina L Brumme
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, BC, Canada
    J Infect Dis 195:1694-704. 2007
  10. pmc Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection
    Vikram S Gill
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    Clin Infect Dis 50:98-105. 2010

Detail Information

Publications75

  1. pmc Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
    P R Harrigan
    Clinical Virology, Glaxo Wellcome Research and Development, Stevenage, United Kingdom
    J Virol 72:3773-8. 1998
    ....
  2. ncbi request reprint Selection of drug-resistant HIV
    P R Harrigan
    BC Centre for Excellence in HIV AIDS, Vancouver, Canada
    Trends Microbiol 7:120-3. 1999
    ..Recent studies have measured the changing proportions of HIV populations, which differ by single nucleic acids, under the selective pressures exerted by the addition or removal of antiretroviral drugs...
  3. pmc Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS
    Adrian R Levy
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
    Lipids Health Dis 4:4. 2005
    ..Protease inhibitors are known to alter the lipid profiles in subjects treated for HIV/AIDS. However, the magnitude of this effect on plasma lipoproteins and lipids has not been adequately quantified...
  4. pmc Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART
    Robert S Hogg
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    PLoS Med 3:e356. 2006
    ..The objective of this study was to determine the impact of the emergence of drug-resistance mutations on survival among persons initiating HAART...
  5. ncbi request reprint Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy
    Magdalena A Recsky
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    J Infect Dis 190:285-92. 2004
    ....
  6. doi request reprint Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial
    Rachel A McGovern
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 61:279-86. 2012
    ..We retrospectively evaluated treatment response after rescreening for viral tropism using population-based V3-loop sequencing...
  7. ncbi request reprint Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy
    Zabrina L Brumme
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    Antivir Ther 8:91-6. 2003
    ..1). The data suggest that HIV p6Gag insertions are not exclusively related to drug resistance and may not influence response to antiretroviral therapy, but may be linked to sequence variations in the HIV envelope...
  8. ncbi request reprint Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy
    P Richard Harrigan
    British Columbia Centre for Excellence in HIV AIDS, and Department of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 191:339-47. 2005
    ....
  9. ncbi request reprint Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy
    Zabrina L Brumme
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, BC, Canada
    J Infect Dis 195:1694-704. 2007
    ....
  10. pmc Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection
    Vikram S Gill
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    Clin Infect Dis 50:98-105. 2010
    ....
  11. doi request reprint CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals
    Andrew J Low
    B C Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    AIDS Res Hum Retroviruses 24:219-28. 2008
    ..The ability to predict X4 virus using genotypic determinants at positions 25 and 6-8 of the V3 loop is CD4 dependent, while position 11 appears to be CD4 independent...
  12. ncbi request reprint Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy
    Zabrina L Brumme
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, The Faculty of Medicine, University of British Columbia, 603 1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6
    AIDS 18:F1-9. 2004
    ..We wished to determine the impact of specific V3 genotypes associated with viral phenotype and co-receptor usage on response to initial triple antiretroviral therapy...
  13. doi request reprint Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine
    Sonia Gutierrez
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, University of British Columbia, Vancouver, Canada
    Clin Infect Dis 46:e28-30. 2008
    ..We provide supporting evidence for the role of tenofovir in the management of advanced HBV infection in HIV-positive patients after the development of lamivudine resistance...
  14. ncbi request reprint Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals
    Zabrina L Brumme
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, and Faculty of Medicine, University of British Columbia, Canada
    J Infect Dis 192:466-74. 2005
    ..We wished to characterize the epidemiological and clinical correlates of CXCR4-using human immunodeficiency virus type 1 (HIV-1) ("X4 variants") in a cross-sectional analysis of a large population of antiretroviral-naive individuals...
  15. ncbi request reprint Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy
    P Richard Harrigan
    BC Centre for Excellence in HIV AIDS, Vancouver, BC, Canada
    Antivir Ther 8:395-402. 2003
    ....
  16. ncbi request reprint Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy
    Viviane D Lima
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    AIDS 21:685-92. 2007
    ..To characterize the temporal changes in mortality and life expectancy among HIV-positive individuals initiating antiretroviral therapy in British Columbia, Canada, from 1993 to 2004...
  17. ncbi request reprint The impact of adherence on CD4 cell count responses among HIV-infected patients
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, BC, Canada
    J Acquir Immune Defic Syndr 35:261-8. 2004
    ....
  18. ncbi request reprint Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, 667 1081 Burrard Street, Vancouver, BC, Canada
    AIDS 20:1117-23. 2006
    ..There is uncertainty regarding the optimal strategy for patients with high plasma HIV RNA but CD4 cell count > or = 200 cells/microl...
  19. pmc HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy
    Celia Chui
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    AIDS Res Hum Retroviruses 22:615-8. 2006
    ..1). The high prevalence and the lack of association with pretherapy clinical parameters in this cohort argue against an association of R77Q with LTNP status. These results do not support an association between R77Q and HAART response...
  20. ncbi request reprint Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, and Department of Health Care and Epidemiology, University of British Columbia, Vancouver, Canada
    J Infect Dis 188:1421-5. 2003
    ..71; 95% confidence interval, 1.08-2.70; P=.023). If appropriately confirmed, these findings have important implications for the development of therapeutic guidelines...
  21. ncbi request reprint Improved detection of CXCR4-using HIV by V3 genotyping: application of population-based and "deep" sequencing to plasma RNA and proviral DNA
    Luke C Swenson
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, Canada
    J Acquir Immune Defic Syndr 54:506-10. 2010
    ..Tropism testing should rule out CXCR4-using HIV before treatment with CCR5 antagonists. Currently, the recombinant phenotypic Trofile assay (Monogram) is most widely utilized; however, genotypic tests may represent alternative methods...
  22. ncbi request reprint Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy
    Nelson Lee
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    J Infect Dis 188:137-41. 2003
    ..Over the short-term, patients receiving MDRT had relatively low mortality. After adjustment for baseline prognostic factors, rates of survival were comparable with those in patients initiating triple-drug ART...
  23. pmc Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes
    Guinevere Q Lee
    BC Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    AIDS Res Hum Retroviruses 29:979-84. 2013
    ..Collective analysis of non-B subtypes revealed a performance similar to subtype B, whereas a subtype-specific analysis revealed overestimation (subtype D) or underestimation (subtype A)...
  24. ncbi request reprint Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease
    Christopher S Alexander
    British Columbia Centre for Excellence in HIV AIDS, University of British Columbia, Vancouver, British Columbia, Canada
    J Infect Dis 188:541-8. 2003
    ..01). These results may reflect incomplete adherence, since a strong association (P<.001) was found between low drug levels and an imperfect prescription-refill record (<95%)...
  25. pmc Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients
    Luke C Swenson
    BC Centre for Excellence in HIV AIDS, Vancouver, Canada
    J Infect Dis 203:237-45. 2011
    ..We retrospectively examined the performance of a genotypic tropism assay based on deep sequencing of the HIV env V3 loop in predicting virologic response to maraviroc in these trials...
  26. ncbi request reprint Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen
    Zabrina L Brumme
    B C Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    Antivir Ther 10:849-53. 2005
    ..Here we investigate associations between CCR5delta32 and HAART outcomes in a large, population-based cohort of >1000 antiretroviral-naive individuals initiating triple therapy over a median >5 year follow-up...
  27. ncbi request reprint Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, Canada
    AIDS 19:1189-95. 2005
    ....
  28. ncbi request reprint Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients
    Elizabeth Phillips
    British Columbia Centre for Excellence in HIV AIDS, Providence Healthcare, St Paul s Hospital, 667 1081 Burrard Street, Vancouver, BC, Canada
    AIDS 21:1561-8. 2007
    ....
  29. doi request reprint Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc
    Luke C Swenson
    BC Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    Clin Infect Dis 53:732-42. 2011
    ..Results were compared with those obtained using the Enhanced Sensitivity Trofile Assay (ESTA), which is widely used in clinical practice...
  30. doi request reprint Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing
    Luke C Swenson
    BC Centre for Excellence in HIV AIDS, Vancouver, Canada
    Clin Infect Dis 56:1659-66. 2013
    ..Here we assess genotypic testing of cellular human immunodeficiency virus (HIV) DNA from peripheral blood mononuclear cells (PBMCs) to predict virologic responses in treatment-experienced patients beginning maraviroc-containing regimens...
  31. ncbi request reprint Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates
    Andrew J Low
    B C Centre for Excellence in HIV AIDS St Paul s Hospital, Vancouver, British Columbia, Canada
    AIDS 21:F17-24. 2007
    ..Integrating CCR5 antagonists into clinical practice would benefit from accurate assays of co-receptor usage (CCR5 versus CXCR4) with fast turnaround and low cost...
  32. pmc Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1
    Art F Y Poon
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    Mol Biol Evol 27:819-32. 2010
    ..Phylogenetic reconstruction from these data revealed correlated substitutions at Y120/Q125 or N157/S169 repeated across multiple lineages in every host, indicating convergent within-host evolution shaped by epistatic interactions...
  33. pmc Factors influencing the sensitivity and specificity of conventional sequencing in human immunodeficiency virus type 1 tropism testing
    David J H F Knapp
    BC Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    J Clin Microbiol 51:444-51. 2013
    ..75; P << 0.001); however, concordance in tropism inference was only 83%. Input copy number and PCR replication are important factors in minority species detection in samples with significant heterogeneity...
  34. pmc "Dynamic range" of inferred phenotypic HIV drug resistance values in clinical practice
    Luke C Swenson
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    PLoS ONE 6:e17402. 2011
    ..Virtual' or inferred phenotypes (vPhenotypes) are commonly used to assess resistance to antiretroviral agents in patients failing therapy. In this study, we provide a clinical context for understanding vPhenotype values...
  35. ncbi request reprint A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase
    Celia K S Chui
    British Columbia Centre for Excellence in HIV AIDS, University of British Columbia, Vancouver, Canada
    Clin Infect Dis 44:1503-8. 2007
    ....
  36. pmc Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
    Julio S G Montaner
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, Vancouver, BC, Canada
    Lancet 376:532-9. 2010
    ..We aimed to estimate the association between plasma HIV-1 viral load, HAART coverage, and number of new cases of HIV in the population of a Canadian province...
  37. pmc The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes
    Lily W Y Tam
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Vancouver, Canada
    J Acquir Immune Defic Syndr 49:266-71. 2008
    ....
  38. pmc Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, Canada
    BMJ 338:b1649. 2009
    ..To examine the relation between plasma HIV-1 RNA concentrations in the community and HIV incidence among injecting drug users...
  39. ncbi request reprint HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach
    P Richard Harrigan
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Infect Dis 191:1325-30. 2005
    ..Our results suggest that analysis of a combined historical genotype rather than of a cross-sectional genotype may lead to more accurate estimates of antiretroviral drug resistance in individual patients and in patient populations...
  40. ncbi request reprint Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA
    Julio S G Montaner
    BC Centre for Excellence in HIV AIDS and the Canadian HIV Trials Network, St Paul s Hospital, Providence Health Care, University of British Columbia, Vancouver, Canada
    Clin Infect Dis 38:S73-9. 2004
    ..A statistically significant increase in the mtDNA : nDNA ratio was observed after the discontinuation of antiretroviral therapy. Full validation of monitoring the mtDNA : nDNA ratio is currently under way...
  41. ncbi request reprint Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response
    Zabrina L Brumme
    B C Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, Canada
    AIDS 17:201-8. 2003
    ....
  42. ncbi request reprint Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors
    P Richard Harrigan
    BC Centre for Excellence in HIV AIDS, Vancouver, BC, Canada
    AIDS 19:549-54. 2005
    ..The prevalence and resistance profile of HIV-1 with other substitutions at RT codon 103 is less well documented...
  43. ncbi request reprint Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens
    Helene C F Cote
    B C Centre for Excellence in HIV AIDS, St Paul s Hospital, Department of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 187:1972-6. 2003
    ..24 months; P<.01). Because of survivor-bias effect, these results may represent a conservative estimate of these nucleosides' effect on mtDNA...
  44. pmc Application and validation of case-finding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada
    Bohdan Nosyk
    BC Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    PLoS ONE 8:e54416. 2013
    ..To define a population-level cohort of individuals infected with the human immunodeficiency virus (HIV) in the province of British Columbia from available registries and administrative datasets using a validated case-finding algorithm...
  45. ncbi request reprint Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy
    Julio S G Montaner
    British Columbia Centrefor Excellence in HIV AIDS and the Canadian HIV Trials Network, St Paul s Hospital, Providence Health Care, University of British Columbia, Vancouver, Canada
    J Acquir Immune Defic Syndr 34:S85-90. 2003
    ..These results suggest that measurement of this parameter should be investigated as a potential clinical management tool...
  46. ncbi request reprint Transmission of drug-resistant HIV-1 from an infected individual to a caregiver
    Chanson J Brumme
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, BC, Canada
    Antivir Ther 12:1139-44. 2007
    ..To describe a suspected case of intrafamilial transmission of drug-resistant HIV-1 from an infected individual to his caregiver...
  47. ncbi request reprint A 21-base pair insertion/duplication at codon 69 of the HIV type 1 reverse transcriptase in a patient undergoing multiple nucleoside therapy
    P Richard Harrigan
    BC Centre for Excellence in HIV AIDS, Vancouver, BC, Canada
    AIDS Res Hum Retroviruses 23:895-9. 2007
    ..These observations may offer new insight into the relative contribution of HIV-RT codon 69 insertion mutations to antiretroviral resistance...
  48. ncbi request reprint Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy?
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 38:289-95. 2005
    ..We evaluated whether baseline CD4 cell count and plasma HIV RNA predicted virologic suppression (<500 copies/mL) and rebound (> or =500 copies/mL) among adherent HIV-infected patients...
  49. doi request reprint Epidemiology of antiretroviral multiclass resistance
    Viviane D Lima
    St Paul s Hospital, 1081 Burrard Street, Room 608, Vancouver, British Columbia V6Z 1Y6, Canada
    Am J Epidemiol 172:460-8. 2010
    ....
  50. ncbi request reprint When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, BC V6Z 1Y6, Canada
    Lancet Infect Dis 5:407-14. 2005
    ....
  51. doi request reprint Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation
    Mark W Hull
    Canadian HIV Trials Network, Vancouver, Canada
    J Clin Pharmacol 49:155-61. 2009
    ....
  52. pmc Comparative Performances of HIV-1 RNA Load Assays at Low Viral Load Levels: Results of an International Collaboration
    Luke C Swenson
    BC Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    J Clin Microbiol 52:517-23. 2014
    ..Correlation and concordance between the viral load assays were lower at a low pVL. Clear guidelines are needed on the clinical significance of low-level viremia. ..
  53. ncbi request reprint Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L
    Evan Wood
    St Paul s Hospital and University of British Columbia, Vancouver, British Columbia, Canada
    Ann Intern Med 139:810-6. 2003
    ..The safety of delaying highly active antiretroviral therapy (HAART) in HIV-infected patients is uncertain when the CD4+ cell count declines below 0.350 x 10(9) cells/L...
  54. ncbi request reprint Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, Canada
    AIDS 17:711-20. 2003
    ..We evaluated whether non-immune-based factors such as physician experience and adherence could affect survival among HIV-infected adults starting HAART...
  55. ncbi request reprint Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy
    Helene C F Cote
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, Vancouver, BC, Canada
    Antivir Ther 11:79-86. 2006
    ..Mitochondrial nephrotoxicity was investigated as an underlying mechanism. Given the interaction between TDF and didanosine (ddl), their concurrent use was also investigated...
  56. ncbi request reprint Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, Canada
    Rev Invest Clin 56:232-6. 2004
    ..200 x 10(9) cells/L regardless of plasma HIV RNA levels and outlines supporting data from a Canadian prospective cohort study of antiretroviral naive patients treated with HAART...
  57. ncbi request reprint No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy
    Zabrina L Brumme
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    AIDS 16:1929-33. 2002
    ....
  58. pmc Development and validation of a composite programmatic assessment tool for HIV therapy
    Viviane D Lima
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    PLoS ONE 7:e47859. 2012
    ..We hypothesized that non-compliance would be associated with the highest probability of mortality...
  59. doi request reprint Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1
    David J H F Knapp
    BC Centre for Excellence in HIV AIDS, Vancouver, Canada
    Clin Infect Dis 54:1652-9. 2012
    ..Here, we characterize the incidence and clinical correlates of HLA-associated evolution in HIV-1 Pol after HAART initiation in a large, population-based observational cohort...
  60. pmc Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool
    Conan K Woods
    BC Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    J Clin Microbiol 50:1936-42. 2012
    ..The time-consuming, error-prone, and dreadfully boring manual sequence analysis step is replaced with a fully automated system without compromising the accuracy of reported HIV drug resistance data...
  61. ncbi request reprint HIV coreceptor phenotyping in the clinical setting
    Andrew J Low
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, BC, Canada Faculty of Medicine, University of British Columbia, Vancouver, Canada
    AIDS Rev 10:143-51. 2008
    ....
  62. ncbi request reprint Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence
    Evan Wood
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, BC, Canada
    AIDS 18:2432-4. 2004
  63. ncbi request reprint Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection
    Christopher S Alexander
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    Ther Drug Monit 26:516-23. 2004
    ..Evening trough concentrations were the best estimators of the daily nadir; however, no adequate substitute for collecting blood 12 hours postdose emerged from this analysis...
  64. doi request reprint Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency
    P Richard Harrigan
    BC Centre for Excellence in HIV AIDS, Vancouver, British Columbia, Canada
    AIDS 22:2501-8. 2008
    ..Missense mutations in HIV-1 reverse transcriptase are frequently selected in response to therapy; we examined whether silent mutations were also selected for by HIV therapy...
  65. doi request reprint Epidemiology of treatment failure: a focus on recent trends
    Mark W Hull
    BC Centre for Excellence in HIV AIDS, Simon Fraser University, Vancouver, British Columbia, Canada
    Curr Opin HIV AIDS 4:467-73. 2009
    ..This review will highlight recent trends in treatment failure and virologic resistance in the developed world and resource-limited settings...
  66. pmc Technical and regulatory shortcomings of the TaqMan version 1 HIV viral load assay
    Chanson J Brumme
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, Canada
    PLoS ONE 7:e43882. 2012
    ..Changes to the limits of detection and calibration have not been validated for clinical utility. Sudden increases in the number of patients with detectable pVL have been reported following the introduction of the TaqMan version 1 assay...
  67. doi request reprint Blood mitochondrial DNA mutations in HIV-infected women and their infants exposed to HAART during pregnancy
    Marissa H J Jitratkosol
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
    AIDS 26:675-83. 2012
    ..We hypothesized that HAART-exposed/HIV-uninfected infants may show higher blood mtDNA mutation burden than controls born to HIV-uninfected mothers...
  68. doi request reprint Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies
    Rachel A McGovern
    BC Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    AIDS 24:2517-25. 2010
    ..This analysis retrospectively examined the performance of population-based sequence analysis of HIV-1 env V3-loop to predict coreceptor tropism...
  69. pmc Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level
    Viviane D Lima
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, Vancouver, British Columbia, Canada
    J Acquir Immune Defic Syndr 55:460-5. 2010
    ..To model the effect of adherence and duration of viral suppression on the risk of viral rebound...
  70. doi request reprint Dates of HIV infection can be estimated for seroprevalent patients by coalescent analysis of serial next-generation sequencing data
    Art F Y Poon
    BC Centre for Excellence in HIV AIDS, Vancouver, Canada
    AIDS 25:2019-26. 2011
    ..To reconstruct dates of HIV infection by the coalescent analysis of longitudinal next-generation sequencing (NGS) data...
  71. ncbi request reprint 2004: which HIV-1 drug resistance mutations are common in clinical practice?
    Peter K Cheung
    BC Centre for Excellence in HIV AIDS, University of British Columbia, Vancouver, Canada
    AIDS Rev 6:107-16. 2004
    ..The tremendous capacity of HIV to adapt means that common resistance pathways are likely to change over time, and new pathways to resistance are likely to continue to be discovered in the future...
  72. ncbi request reprint The direct costs of HIV/AIDS care
    Adrian R Levy
    Department of Health Care and Epidemiology, University of British Columbia, Vancouver, BC, Canada
    Lancet Infect Dis 6:171-7. 2006
    ..Although this information is important for planning purposes, only a small number of published studies provide useful estimates of the direct cost. A useful method of estimating resource use and costs is computer simulation...
  73. ncbi request reprint The impact of human genetic variation on HIV disease in the era of HAART
    Zabrina L Brumme
    BC Centre for Excellence in HIV AIDS, Vancouver, Canada
    AIDS Rev 8:78-87. 2006
    ....
  74. ncbi request reprint The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic
    Julio S G Montaner
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, University of British Columbia, Vancouver, Canada
    Lancet 368:531-6. 2006
  75. ncbi request reprint Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants
    Helene C F Cote
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 198:851-9. 2008
    ....